Glen Iris home sells $150k above price guide
The three-bedroom home at 2 Charles St had been quoted a $1.25m-$1.35m price guide, but five bidders, including a neighbour, helped push the result $50,000 above the top of the range.
While the weather was icy, competition was anything but, with Buxton ACOM director and auctioneer Peter Gigis declaring it one of the cleanest and most confident winter auctions he's handled in recent memory.
Inside 'Hospitality Yoda's luxe Melb home
'The property was announced on the market at $1.25m and ended up selling for $1.4m,' Mr Gigis said.
'It was a solid result, especially for a single-level home in Glen Iris, which continues to be in high demand.'
Mr Gigis said the picture-perfect property on 301sq m charmed older buyers with its stand-alone layout, mature gardens and sun-soaked courtyard, all within walking distance of Burwood Village, light rail and the upcoming Suburban Rail Loop station.
'Downsizers were the dominant force here. At least four of the strongest bidders were older couples who'd just sold in the area,' he said.
'But in the end, it was a young couple who secured the keys, and the vendors, a brother and sister who'd inherited the home, were thrilled.'
The neat interiors include a front lounge, open-plan kitchen and dining zone, and three robed bedrooms, including one with direct bathroom access.
Extras like ducted heating, evaporative cooling, ducted vacuum and a remote garage with second car space added to the turnkey appeal, while the wraparound courtyard offered leafy privacy and an outdoor entertaining zone.
The Buxton ACOM director said demand across Ashburton, Camberwell, Oakleigh and Mount Waverley had ramped up noticeably this winter.
'This is easily the strongest winter market we've seen since before Covid,' Mr Gigis said.
'Stock's still incredibly tight, especially in places like Glen Iris and Ashburton, and buyers are acting fast when the right home comes up.'
Mr Gigis The fact 2 Charles St had no common land was a rare and highly prized feature.
'You can find units and villas in Glen Iris, but not many that are stand-alone like this one. That made a huge difference,' he said.
Mr Gigis expects a spring surge to follow once the July lull clears, with rate relief and low listings creating a perfect storm for sellers.
'We're already seeing momentum build for September,' he said.
There's definitely more confidence than there was last year, buyers and sellers alike are getting ready.'
The sale was managed by Mr Gigis alongside Buxton Oakleigh's Emily Duvnjak.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
23 minutes ago
- News.com.au
Top 10 at 11: ASX jumps on open as copper and battery metals rally
Morning, and welcome to Stockhead's Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am, once trading kicks off in earnest. In brief, this is what the market has been up to this morning. Resources drive early gains The ASX 200 has jumped 0.42% in the first half hour of trading, with 9 of 11 sectors making gains as of about 10:30 am AEST. The materials sector is leading the charge, building on momentum generated by a rally in lithium and battery metal stocks and a 5.9% jump in James Hardie (ASX:JHX) shares. The construction materials company completed its acquisition of NYSE-listed outdoor living business AZEK today, adding to its extensive portfolio of exterior design brands. Lithium, rare earth and copper stocks are making the biggest moves this morning, including several of the stocks on our small cap winners list… WINNERS Code Name Last % Change Volume Market Cap PKO Peako Limited 0.003 50% 120000 $2,975,484 EEL Enrg Elements Ltd 0.002 33% 792525 $4,880,668 IS3 I Synergy Group Ltd 0.002 33% 620409 $2,253,285 SRN Surefire Rescs NL 0.002 33% 1500000 $3,729,668 LAT Latitude 66 Limited 0.029 26% 10932 $3,298,216 ADG Adelong Gold Limited 0.005 25% 60000 $8,274,707 DY6 Dy6Metalsltd 0.145 23% 1246772 $8,749,344 HOR Horseshoe Metals Ltd 0.025 19% 670720 $14,070,141 BCA Black Canyon Limited 0.16 19% 405899 $17,502,844 ID8 Identitii Limited 0.007 17% 15000 $4,668,081 In the news... Horseshoe Metals (ASX:HOR) is preparing to fire up its direct shipping ore operations for the Horseshoe Lights copper-gold project in WA, after getting the greenlight from the DEMIRS. HOR expects to have boots on the ground within the next few weeks, with sales of existing copper stockpiles to begin shortly thereafter. It's perfect timing for the company, with the price of copper soaring more than 26% in the year to date to reach 10-year highs. Latitude 66 (ASX:LAT) is offloading its 17.5% interest in the Greater Duchess joint venture project, triggering a right of first refusal for JV partner Carnaby Resources (ASX:CNB). LAT is looking to sell its interest for $2m, with some conditional payments on the table of up to $4m in cash or ASX-listed shares. If the project is sold within 90 days of the sale and anyone can get their hands on 100% of the project interest, LAT will be $4m richer; if only a partial sale is made in that time, the company will earn 50% of any proceeds above $4m. LAGGARDS Code Name Last % Change Volume Market Cap AOA Ausmon Resorces 0.001 -50% 111800 $2,622,427 VHL Vitasora Health Ltd 0.03 -23% 3864299 $61,504,061 MMR Mec Resources 0.004 -20% 504034 $9,248,829 PIL Peppermint Inv Ltd 0.002 -20% 100000 $5,752,724 C29 C29Metalslimited 0.015 -17% 1772692 $3,135,388 CUS Coppersearchlimited 0.016 -16% 100593 $3,018,941 RDS Redstone Resources 0.003 -14% 150000 $3,619,936 RNX Renegade Exploration 0.0035 -13% 616666 $5,153,454 CPV Clearvue Technologie 0.14 -13% 368291 $42,980,027 NYM Narryermetalslimited 0.031 -11% 101959 $6,161,918
News.com.au
23 minutes ago
- News.com.au
Health Check: Like bloodthirsty sharks, offshore acquirers are circling cheap biotech assets
As today's Medadvisor deal attests, underperforming biotech assets are getting a bite or two Next Science shares continue to rally, but the company is still valued at less than Demant's offer price for most of its assets Neurizon enters a key deal with the supplier of its drug candidate for motor neurone disease Inspired by the 50 th anniversary of the original Jaws movie, local and offshore predators are on the hunt for local biotech prey. Today, medication compliance group MedAdvisor (ASX:MDR) said it had entered a binding agreement to sell its Australian ops to the Canadian owned Jonas Software, for a headline $35 million. As we reported yesterday, Medadvisor was the worst performing ASX-listed biotech last financial year, sinking 82%. Yesterday, struggling wound management company Next Science (ASX:NXS) proposed a US$50 million ($75 million) deal to sell most of its assets. The buyer is the Milan based Demetra Holdings (see below). Mayne Pharma (ASX:MYX) is – or was – subject to a $600 million offer from US dermatology group Cosette, but the suitor spat out the arm after due diligence (allegedly) revealed horrors lurking in depths. As with the makers of the epic Jaws movie, we must apologise to the sea's apex predators for besmirching their reputation. Unlike with the six remarkably careless Jaws 1 victims, biotech's metaphorical equivalent is usually most welcome. Medadvisor prefers US focus Coming back to Medadvisor, the company wants to focus on its bigger US business, which provides prescription drug information services to patients via big pharma and chemists. The terms are like the non-binding ones announced on May 9. One quirk is that the deal includes the Medadvisor moniker, but Medadvisor can continue to use that name under a royalty-free arrangement. Still, the company will seek shareholder approval to change its name. While Medadvisor pockets $35 million now, it has dibs on an 'uncapped contingent consideration' based on the divested arm's performance. On current trends, the company would expect another $7.35 million. Medadvisor intends to use some of the proceeds to discharge a $23.5 million finance facility. The company will use the remainder pending a review of its US operations, which have been hit by a downturn in vaccination rates. This has resulted in the jab makers winding back promotional spend. Next Science investors retain zeal for deal Having pushed up Next Science shares 64% yesterday, investors today added another 9% on the back of the proposal that in effect will see their company disappear. The proposal is subject to the consent of Next Science shareholders at a meeting scheduled on August 14. In framing the friendly deal, Demetra no doubt has chatted to Next Science's 37% shareholder, property tycoon and biotech dabbler Lang Walker. The deal is also subject to an independent expert report. Next Science intends to redistribute to shareholders the estimated US$30 million remaining after winding up costs. With approved products in the US, Next Science operates in wound care and surgical infection control. Demetra supplies bone cement, for fixing orthopaedic implants and the like. Next Science's regally dubbed CEO, Harry Hall IV says that in Demetra's more capacious hands Next Science's products 'will be better positioned to realise their full potential in improving patient care globally'. Next Science listed at $1 in April 2019 in a $35 million IPO and peaked at close to $2 in mid 2021. It's been downhill from there. Meanwhile the ASX circle of life continues, with wound management house Tetratherix (ASX:TTX) listing successfully last Monday. Interestingly, Next Science still bears a market cap of a mere $34 million. Neurizon does 'vet' deal but it's not going to the dogs The developer of a repurposed drug candidate for a form of motor neurone disease, Neurizon Therapeutics (ASX:NUZ) has entered an exclusive global licensing agreement with the New York-listed Elanco Animal Health. The deal doesn't take Neurizon back into veterinary drugs, the company's key remit when it was known as Pharmaust. But Elanco is the exclusive maker of the drug candidate – monepantel – which regulators originally approved as a sheep drench. Monepantel is the active component of NUZ-001, Neurizon's lead therapy for amyotrophic lateral sclerosis (ALS) and other human neurodegenerative diseases. The deal bestows Neurizon with the global rights for Elanco's intellectual property, including extensive non-clinical (animal) and manufacturing data. The agreement also outlines key terms for Elanco's future supply of monepantel, with a formal agreement expected in the current half. Monepantel works by inhibiting the mTOR signalling pathway, which plays a central role in the growth of cancer cells and the degeneration of neurons. mTOR stands for the 'mechanistic Target of Rapamycin', a reference not to a Tolkien novel but a well-known oncology target (rapamycin). Neurizon is participating in Healey ALS, a collaborative MND trial across 70-plus sites in the US. The platform will test several drugs simultaneously, thus increasing patient access and reducing study costs and completion and enrolment times. Neurizon CEO Dr Michael Thurn says the deal should 'dramatically reduce near-term development costs and accelerate development timelines.' The deal involves a nominal up-front payment and back-ended development milestones of US$9.75 million for the initial product. Should sales take off, Neurizon pays sales milestones of up to US$65 million but we'll cross that bridge when we come to it. Emvision's Emu hops to five sites, with one more to come The developer of a portable bedside stroke scanner dubbed Emu, EMvision Medical Devices (ASX:EMV) hopes to sign up its sixth and final site for its pivotal trial pitched at regulatory approval. The company today said five sites – three in the US and two locally – were now 'actively enrolling and scanning patients'. The three US sites are New York's Mt Sinai Hospital, Florida's Mayo Clinic and UT Health Memorial Hermann Texas Medical Centre. The local sites are Royal Melbourne Hospital and Sydney's Liverpool Hospital. The sixth site, at a west coast US clinic, should be announced 'shortly'. Emvision also won assent to start a continuous innovation study for stroke and traumatic brain injury patients, at Newcastle's John Hunter Hospital and Brisbane's Princess Alexandra Hospital. The trial involves enrolling up to 300 suspected stroke victims. Clinicians will assess them in the normal manner along with an Emu scan. The study aims to determine accurately whether a stroke is a blood clot or a bleed. If Emu takes flight, the company plans to seek expedited US approval for an ambulance variant, called First Responder.
News.com.au
an hour ago
- News.com.au
China flexing its muscles in ways that ‘differ from Australia's interests'
China is 'asserting its influence' in ways that do not align with Australia's national interest, Foreign Minister Penny Wong says. Senator Wong is in Washington for a Quad summit with her Indian, Japanese and US counterparts. The Quad is a partnership broadly seen as a check on China's economic and increasingly militaristic might. Fronting media on Wednesday (AEST), Senator Wong said the four countries were under no illusions about the threats posed by China. 'China is a great power,' she told reporters in the US capital. 'It is asserting its influence using all aspects of national power. 'The challenge for Australia and for other countries is that … one can see where those interests differ from Australia's interests.' Pacific power grabbing and threatening freedom of navigation are among Canberra's key grievances with Beijing. The Albanese government has spent billions on countering China's efforts to boost its sway in the region, including by debt-trapping Australia's smaller Pacific neighbours. The Chinese government has also stepped up military activity in the South China Sea and around the democratically self-governed island of Taiwan, threatening key shipping lanes that Australia depends upon. 'Certainly … China has interests, which it presses, which are not the same as our interests,' Senator Wong said. 'And we have to navigate that, and we do that and we have not stepped back as a government from those things where we disagree, but we will continue to engage.' She repeated the Albanese government's mantra on China, saying 'we co-operate where we can, disagree where we must'. Despite the tough words, Senator Wong said she and State Secretary Marco Rubio did not discuss Australia's defence spending. The Trump administration last month requested the Albanese government hike the military budget to 3.5 per cent of GDP. The demand ignited a furious debate that has somewhat poured cold water on Anthony Albanese's post-election high amid severe scrutiny over his relationship with Donald Trump. 'The issue of Australia's defence budget was not raised with me, either in the Quad or in my bilateral meeting,' Senator Wong said. 'What we did discuss is a number of areas of co-operation that we want to see more concrete outcomes … critical minerals is one of them, maritime security is another.'
